Total unique templates: 104


[1] Count: 59980
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_B.
--------------------------------------------------------------------------------

[2] Count: 39293
Template: The metabolism of DRUG_B can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[3] Count: 33077
Template: The serum concentration of DRUG_B can be DIRECTION when it is combined with DRUG_A.
--------------------------------------------------------------------------------

[4] Count: 8145
Template: DRUG_A may DIRECTION the hypotensive activities of DRUG_B.
--------------------------------------------------------------------------------

[5] Count: 7902
Template: The therapeutic efficacy of DRUG_B can be DIRECTION when used in combination with DRUG_A.
--------------------------------------------------------------------------------

[6] Count: 6137
Template: DRUG_A may DIRECTION the QTc-prolonging activities of DRUG_B.
--------------------------------------------------------------------------------

[7] Count: 5391
Template: DRUG_A may DIRECTION the central nervous system depressant (CNS depressant) activities of DRUG_B.
--------------------------------------------------------------------------------

[8] Count: 3702
Template: DRUG_A may DIRECTION the antihypertensive activities of DRUG_B.
--------------------------------------------------------------------------------

[9] Count: 3280
Template: DRUG_A may DIRECTION the anticoagulant activities of DRUG_B.
--------------------------------------------------------------------------------

[10] Count: 2109
Template: DRUG_A may DIRECTION the hypoglycemic activities of DRUG_B.
--------------------------------------------------------------------------------

[11] Count: 1814
Template: DRUG_A may DIRECTION the excretion rate of DRUG_B which could result in a higher serum level.
--------------------------------------------------------------------------------

[12] Count: 1565
Template: DRUG_A may DIRECTION the sedative activities of DRUG_B.
--------------------------------------------------------------------------------

[13] Count: 1276
Template: DRUG_A may DIRECTION the bradycardic activities of DRUG_B.
--------------------------------------------------------------------------------

[14] Count: 1233
Template: DRUG_A may DIRECTION the cardiotoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[15] Count: 1130
Template: DRUG_A may DIRECTION the hypokalemic activities of DRUG_B.
--------------------------------------------------------------------------------

[16] Count: 936
Template: DRUG_A may DIRECTION the neuroexcitatory activities of DRUG_B.
--------------------------------------------------------------------------------

[17] Count: 838
Template: DRUG_A can cause a DIRECTION in the absorption of DRUG_B resulting in a DIRECTION serum concentration and potentially a DIRECTION in efficacy.
--------------------------------------------------------------------------------

[18] Count: 792
Template: DRUG_A may DIRECTION the serotonergic activities of DRUG_B.
--------------------------------------------------------------------------------

[19] Count: 716
Template: DRUG_A may DIRECTION the atrioventricular blocking (AV block) activities of DRUG_B.
--------------------------------------------------------------------------------

[20] Count: 673
Template: DRUG_A may DIRECTION the hypertensive activities of DRUG_B.
--------------------------------------------------------------------------------

[21] Count: 660
Template: DRUG_A may DIRECTION the nephrotoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[22] Count: 601
Template: DRUG_A may DIRECTION the orthostatic hypotensive activities of DRUG_B.
--------------------------------------------------------------------------------

[23] Count: 554
Template: DRUG_A may DIRECTION the stimulatory activities of DRUG_B.
--------------------------------------------------------------------------------

[24] Count: 537
Template: The serum concentration of the active metabolites of DRUG_B can be DIRECTION when DRUG_B is used in combination with DRUG_A.
--------------------------------------------------------------------------------

[25] Count: 529
Template: The bioavailability of DRUG_B can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[26] Count: 471
Template: DRUG_A may DIRECTION the neuromuscular blocking activities of DRUG_B.
--------------------------------------------------------------------------------

[27] Count: 441
Template: The risk or severity of QTc prolongation can be DIRECTION when DRUG_A is combined with DRUG_B.
--------------------------------------------------------------------------------

[28] Count: 422
Template: DRUG_A may DIRECTION the fluid retaining activities of DRUG_B.
--------------------------------------------------------------------------------

[29] Count: 418
Template: DRUG_A may DIRECTION the vasoconstricting activities of DRUG_B.
--------------------------------------------------------------------------------

[30] Count: 372
Template: DRUG_A may DIRECTION the tachycardic activities of DRUG_B.
--------------------------------------------------------------------------------

[31] Count: 361
Template: DRUG_A may DIRECTION the bronchodilatory activities of DRUG_B.
--------------------------------------------------------------------------------

[32] Count: 349
Template: DRUG_A may DIRECTION the arrhythmogenic activities of DRUG_B.
--------------------------------------------------------------------------------

[33] Count: 343
Template: DRUG_A may DIRECTION the antiplatelet activities of DRUG_B.
--------------------------------------------------------------------------------

[34] Count: 324
Template: DRUG_A may DIRECTION the diuretic activities of DRUG_B.
--------------------------------------------------------------------------------

[35] Count: 323
Template: DRUG_A may DIRECTION the anticholinergic activities of DRUG_B.
--------------------------------------------------------------------------------

[36] Count: 312
Template: DRUG_A may DIRECTION the immunosuppressive activities of DRUG_B.
--------------------------------------------------------------------------------

[37] Count: 311
Template: The serum concentration of the active metabolites of DRUG_B can be DIRECTION when DRUG_B is used in combination with DRUG_A resulting in a loss in efficacy.
--------------------------------------------------------------------------------

[38] Count: 280
Template: DRUG_A may DIRECTION the analgesic activities of DRUG_B.
--------------------------------------------------------------------------------

[39] Count: 280
Template: DRUG_A may DIRECTION the respiratory depressant activities of DRUG_B.
--------------------------------------------------------------------------------

[40] Count: 278
Template: DRUG_A may DIRECTION the hyperkalemic activities of DRUG_B.
--------------------------------------------------------------------------------

[41] Count: 180
Template: DRUG_A may DIRECTION the hypocalcemic activities of DRUG_B.
--------------------------------------------------------------------------------

[42] Count: 146
Template: DRUG_A may DIRECTION the constipating activities of DRUG_B.
--------------------------------------------------------------------------------

[43] Count: 126
Template: The risk or severity of bleeding can be DIRECTION when DRUG_A is combined with DRUG_B.
--------------------------------------------------------------------------------

[44] Count: 108
Template: DRUG_A may DIRECTION the thrombogenic activities of DRUG_B.
--------------------------------------------------------------------------------

[45] Count: 106
Template: DRUG_A may DIRECTION the hyponatremic activities of DRUG_B.
--------------------------------------------------------------------------------

[46] Count: 94
Template: DRUG_A may DIRECTION the antipsychotic activities of DRUG_B.
--------------------------------------------------------------------------------

[47] Count: 94
Template: DRUG_A may DIRECTION the adverse neuromuscular activities of DRUG_B.
--------------------------------------------------------------------------------

[48] Count: 82
Template: DRUG_A can cause an DIRECTION in the absorption of DRUG_B resulting in an DIRECTION serum concentration and potentially a worsening of adverse effects.
--------------------------------------------------------------------------------

[49] Count: 76
Template: DRUG_A may DIRECTION the hypercalcemic activities of DRUG_B.
--------------------------------------------------------------------------------

[50] Count: 69
Template: DRUG_A may DIRECTION the myopathic rhabdomyolysis activities of DRUG_B.
--------------------------------------------------------------------------------

[51] Count: 69
Template: DRUG_A may DIRECTION the neurotoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[52] Count: 65
Template: DRUG_A may DIRECTION the vasopressor activities of DRUG_B.
--------------------------------------------------------------------------------

[53] Count: 52
Template: DRUG_A may DIRECTION the hepatotoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[54] Count: 45
Template: The absorption of DRUG_B can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[55] Count: 43
Template: DRUG_A may DIRECTION the ulcerogenic activities of DRUG_B.
--------------------------------------------------------------------------------

[56] Count: 34
Template: DRUG_A may DIRECTION the myelosuppressive activities of DRUG_B.
--------------------------------------------------------------------------------

[57] Count: 33
Template: DRUG_A may DIRECTION effectiveness of DRUG_B as a diagnostic agent.
--------------------------------------------------------------------------------

[58] Count: 33
Template: DRUG_A may DIRECTION the vasodilatory activities of DRUG_B.
--------------------------------------------------------------------------------

[59] Count: 31
Template: DRUG_A may DIRECTION the excretion rate of DRUG_B which could result in a DIRECTION serum level and potentially a reduction in efficacy.
--------------------------------------------------------------------------------

[60] Count: 31
Template: The risk or severity of hypotension can be DIRECTION when DRUG_A is combined with DRUG_B.
--------------------------------------------------------------------------------

[61] Count: 28
Template: DRUG_A may DIRECTION the hyperglycemic activities of DRUG_B.
--------------------------------------------------------------------------------

[62] Count: 27
Template: DRUG_A may DIRECTION the central nervous system depressant (CNS depressant) and hypertensive activities of DRUG_B.
--------------------------------------------------------------------------------

[63] Count: 26
Template: DRUG_A may DIRECTION the bronchoconstrictory activities of DRUG_B.
--------------------------------------------------------------------------------

[64] Count: 26
Template: The risk of a hypersensitivity reaction to DRUG_B is DIRECTION when it is combined with DRUG_A.
--------------------------------------------------------------------------------

[65] Count: 26
Template: The risk or severity of heart failure can be DIRECTION when DRUG_B is combined with DRUG_A.
--------------------------------------------------------------------------------

[66] Count: 21
Template: DRUG_A may DIRECTION the ototoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[67] Count: 14
Template: DRUG_A may DIRECTION the hypotensive and central nervous system depressant (CNS depressant) activities of DRUG_B.
--------------------------------------------------------------------------------

[68] Count: 14
Template: The risk or severity of hypertension can be DIRECTION when DRUG_B is combined with DRUG_A.
--------------------------------------------------------------------------------

[69] Count: 13
Template: DRUG_A may DIRECTION the central neurotoxic activities of DRUG_B.
--------------------------------------------------------------------------------

[70] Count: 11
Template: DRUG_A may DIRECTION the dermatologic adverse activities of DRUG_B.
--------------------------------------------------------------------------------

[71] Count: 11
Template: The protein binding of DRUG_B can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[72] Count: 6
Template: The risk or severity of hyperkalemia can be DIRECTION when DRUG_A is combined with DRUG_B.
--------------------------------------------------------------------------------

[73] Count: 3
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with LevoDRUG_A.
--------------------------------------------------------------------------------

[74] Count: 2
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethylDRUG_A.
--------------------------------------------------------------------------------

[75] Count: 2
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with FluDRUG_A.
--------------------------------------------------------------------------------

[76] Count: 2
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DesDRUG_A.
--------------------------------------------------------------------------------

[77] Count: 1
Template: DRUG_A may DIRECTION the QTc-prolonging activities of LevDRUG_A.
--------------------------------------------------------------------------------

[78] Count: 1
Template: The serum concentration of FosDRUG_A can be DIRECTION when it is combined with DRUG_A.
--------------------------------------------------------------------------------

[79] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with HydroDRUG_A.
--------------------------------------------------------------------------------

[80] Count: 1
Template: The metabolism of FosDRUG_A can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[81] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ButylDRUG_A.
--------------------------------------------------------------------------------

[82] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethDRUG_A.
--------------------------------------------------------------------------------

[83] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ApraDRUG_A.
--------------------------------------------------------------------------------

[84] Count: 1
Template: DRUG_A may DIRECTION the QTc-prolonging activities of CiprDRUG_A.
--------------------------------------------------------------------------------

[85] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DiaDRUG_A.
--------------------------------------------------------------------------------

[86] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with NorDRUG_A.
--------------------------------------------------------------------------------

[87] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_A bromide.
--------------------------------------------------------------------------------

[88] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MethDRUG_A bromide.
--------------------------------------------------------------------------------

[89] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with TrDRUG_A.
--------------------------------------------------------------------------------

[90] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with ChloroDRUG_A.
--------------------------------------------------------------------------------

[91] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with OxybuDRUG_A.
--------------------------------------------------------------------------------

[92] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DRUG_A enacarbil.
--------------------------------------------------------------------------------

[93] Count: 1
Template: The metabolism of MethylDRUG_A can be DIRECTION when combined with DRUG_A.
--------------------------------------------------------------------------------

[94] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with FosDRUG_A.
--------------------------------------------------------------------------------

[95] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with AceDRUG_A.
--------------------------------------------------------------------------------

[96] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with TrifluDRUG_A.
--------------------------------------------------------------------------------

[97] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with EthylDRUG_A.
--------------------------------------------------------------------------------

[98] Count: 1
Template: DRUG_A may DIRECTION the hypotensive activities of DRUG_Aat.
--------------------------------------------------------------------------------

[99] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with DihydroDRUG_A.
--------------------------------------------------------------------------------

[100] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with EsDRUG_A.
--------------------------------------------------------------------------------

[101] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with MeDRUG_A.
--------------------------------------------------------------------------------

[102] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with PseudoDRUG_A.
--------------------------------------------------------------------------------

[103] Count: 1
Template: The risk or severity of adverse effects can be DIRECTION when DRUG_A is combined with HydroxyDRUG_A.
--------------------------------------------------------------------------------

[104] Count: 1
Template: DRUG_A may DIRECTION the excretion rate of UrsodeoxyDRUG_A which could result in a higher serum level.
--------------------------------------------------------------------------------
